Not all niacin products appear to work the same way. In a randomized clinical trial, researchers compared wax-matrix extended-release niacin with inositol hexanicotinate, a supplement commonly marketed as “no-flush” niacin. While the wax-matrix formulation improved LDL, total, HDL, and non-HDL cholesterol, inositol hexanicotinate showed no meaningful benefit beyond placebo. The study also examined how well each formulation was absorbed and whether adjusting the dose could improve tolerability.
Key Findings
- 121 participants were randomized after a four-week heart-healthy diet phase.
- Participants received:
- 1,500 mg/day of wax-matrix extended-release niacin,
- 1,500 mg/day of inositol hexanicotinate, or
- placebo.
- After six weeks, the wax-matrix niacin group experienced:
- 11% lower total cholesterol
- 18% lower LDL cholesterol
- 12% higher HDL cholesterol
- 15% lower non-HDL cholesterol
- Approximately 9% lower triglycerides, although this result did not reach statistical significance
- Inositol hexanicotinate did not significantly improve lipid levels compared with placebo.
- Medication compliance exceeded 92% in all groups.
- One participant in the wax-matrix niacin group discontinued because of flushing, gastrointestinal symptoms, and itching.
- Flushing was reported more often with wax-matrix niacin than with IHN or placebo, but it was generally described as mild among participants who completed treatment.
- Six participants receiving wax-matrix niacin were able to continue the trial after reducing the dose to 500–1,000 mg/day.
- Five of six participants in the reduced-dose WMER group reached their LDL treatment goal.
- The wax-matrix formulation showed measurable absorption over approximately six hours.
- Inositol hexanicotinate showed no meaningful increase in nicotinic acid or its measured metabolites during the pharmacokinetic substudy.
What the Findings Mean for Patients
This study compared two nonprescription forms of niacin marketed for cholesterol management: wax-matrix extended-release niacin and inositol hexanicotinate, commonly referred to as “no-flush” niacin.
After a four-week dietary lead-in, 121 adults with mild-to-moderate dyslipidemia were randomly assigned to receive wax-matrix niacin, inositol hexanicotinate, or placebo for six weeks. The wax-matrix formulation produced significant improvements in several lipid measures, including an 18% reduction in LDL cholesterol, an 11% reduction in total cholesterol, a 12% increase in HDL cholesterol, and a 15% reduction in non-HDL cholesterol.
In contrast, the inositol hexanicotinate group showed no significant improvement compared with placebo. The small pharmacokinetic substudy offered a possible explanation: measurable nicotinic acid and metabolite levels appeared after wax-matrix niacin administration, whereas the IHN group showed little evidence of absorption or bioavailability.
Wax-matrix niacin was generally tolerated, although flushing and gastrointestinal symptoms occurred more frequently than with IHN or placebo. Several participants who did not tolerate the full 1,500-mg dose were able to complete the trial at a lower dose while still achieving meaningful lipid changes.
The findings suggest that different niacin formulations cannot be assumed to have equivalent effects. However, the study was brief, relatively small, and evaluated a specific formulation. It also did not assess cardiovascular outcomes such as heart attacks, strokes, or mortality.
→ Download the Full Text HERE.
